2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Le, Michael; Yeo, Yee Hui; Li, Xiaohe; Li, Jie; Zou, Biyao; Wu, Yuankai; Ye, Qing; Huang, Daniel Q.; Zhao, Changqing; Zhang, Jie; Liu, Chenxi; Chang, Na; Feng, Xing; Shi, Yan; Hui, Wan; Yee, Natasha Tang Sook; Maeda, Manabu; Liu, Xinting; Liu, Chuanli; Rui, Fajuan; Yang, Hongli; Yao, Yang; Jin, Ruichun; Le, Richard HX.; Xu, Yayun; Le, David; Barnett, Scott D.; Stave, Christopher D; Cheung, Ramsey; Zhu, Qiang; Nguyen, Mindie H.

doi:10.1016/j.cgh.2021.12.002

Cited by 406 publications

(304 citation statements)

References 228 publications

Supporting

Mentioning

282

Contrasting

Unclassified

Order By: Relevance

“…1 In a recently published systematic review and meta-analysis, the pooled worldwide prevalence of NAFLD was 29.8%; where 82.5% of included reports relied on ultrasound for NAFLD diagnosis. 9 Despite these issues, the prevalence of NAFLD varies significantly from country to country and even between different regions of the same country. These differences may be due to differences in the age, gender, ethnicity, and dietary patterns of the individuals surveyed.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…These differences may be due to differences in the age, gender, ethnicity, and dietary patterns of the individuals surveyed. [7][8][9][10] Diagnostic techniques utilized to establish NAFLD diagnosis are another source of such geographical variation. Relying on noninvasive blood testing, such as liver enzyme increase, may reduce NAFLD prevalence rates.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

See 1 more Smart Citation

Nonalcoholic Fatty Liver Disease: Current Global Burden

et al. 2022

View full text Add to dashboard Cite

The map and global disease burden of chronic liver diseases are markedly changing, with non-alcoholic fatty liver disease (NAFLD) becoming the most common cause of liver affection coinciding with the current epidemics of obesity, type 2 diabetes, and metabolic syndrome. Understanding the incidence and prevalence of NAFLD is critical because of its linkage to a significant economic burden of hospitalization and changing patterns in consequences such as liver transplantation. Moreover, the long-term average healthcare expenses of NAFLD patients have exceeded those of other liver diseases. To lessen the imminent burden of NAFLD, immediate actions to raise worldwide awareness and address metabolic risk factors are required. This review summarizes key data about the global disease burden of NAFLD, modifiable and non-modifiable risk factors, and current preventive approaches.

show abstract

Section: Accepted Manuscriptmentioning

confidence: 99%

Section: Accepted Manuscriptmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease: Current Global Burden

et al. 2022

View full text Add to dashboard Cite

show abstract

“…NAFLD is a common clinical condition with an estimated prevalence of 23% in Europe, 24% in the USA, 32% in the Middle East, and 27% in Asia [ 18 ]. Recent trend analyses have shown that, in the period 1991–2019, NAFLD increased from 21.9 to 37.3% (yearly increase of 0.7% ( p < 0.0001)) [ 19 ]. NAFLD is relatively more common in men with advancing age but is also observed in obese children and adolescents with sequels similar to those observed in adults [ 20 , 21 ]; in women, the prevalence of NAFLD becomes similar to that of men after menopause [ 22 ].…”

Section: General Features Of Nafldmentioning

confidence: 99%

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences

et al. 2022

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is anticipated that it could become even more prevalent in parallel with an increase in the incidence of metabolic diseases closely related to NAFLD, such as obesity, type II diabetes, dyslipidemia, and arterial hypertension. In addition to liver impairment, NAFLD is associated with cardiovascular diseases. Fibrosis, atherosclerosis, and venous thrombosis are basically the pathogenic mechanisms behind these clinical manifestations, and all are plausibly associated with hypercoagulability that may, in turn, develop because of an imbalance of pro- vs. anticoagulants and the presence of such procoagulant molecular species as microvesicles, neutrophil extracellular traps (NETs), and inflammation. The assessment of hypercoagulability by means of thrombin generation is a global procedure that mimics the coagulation process occurring in vivo much better than any other coagulation test, and is considered to be the best candidate laboratory tool for assessing, with a single procedure, the balance of coagulation in NAFLD. In addition to defining the state of hypercoagulability, the assessment of thrombin generation could also be used to investigate, in clinical trials, the best approach (therapeutic and/or lifestyle changes) for minimizing hypercoagulability and, hence, the risk of cardiovascular diseases, progression to atherosclerosis, and liver fibrosis in patients with NAFLD.

show abstract

“…In this regard, it is important to remember that NAFLD is, to date, the most frequent chronic liver disease observed in clinical practice worldwide [ 1 , 2 ]. It is estimated that NAFLD affects roughly 25–30% of adults in the general population [ 3 ] and nearly 70% of patients with type 2 diabetes (T2DM) [ 4 , 5 ]. Of note, in recent decades it has become clear that NAFLD is associated with liver-related complications, but also with metabolic, cardiovascular and renal complications [ 2 ].…”

mentioning

confidence: 99%